EMPLOYMENT AGREEMENTEmployment Agreement • January 6th, 2021 • Heat Biologics, Inc. • Pharmaceutical preparations • Delaware
This EMPLOYMENT AGREEMENT (the “Agreement”) between Heat Biologics, Inc., a Delaware corporation, (the “Company”), and Jeffrey Wolf (the “Executive”) is effective as of January 4, 2021 (the “Effective Date”).
HEAT BIOLOGICS, INC. RESTRICTED STOCK AGREEMENTRestricted Stock Agreement • January 6th, 2021 • Heat Biologics, Inc. • Pharmaceutical preparations • Delaware
THIS RESTRICTED STOCK AGREEMENT (the “Agreement”) is made and entered into as of (the “Grant Date”), by and between Heat Biologics, Inc., a Delaware corporation (the “Company”), and _________ (the “Participant”).
UNIVERSITY OF MIAMI EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • January 6th, 2021 • Heat Biologics, Inc. • Pharmaceutical preparations • Florida
This Exclusive License Agreement (this “Agreement”) is entered into and made effective as of the last dated signature below (the “Effective Date”) between University of Miami, a Florida not-for-profit corporation, having business offices at 1951 NW 7th Avenue, Suite 300, Miami, Florida 33136 (“UNIVERSITY”) and Zolovax, Inc., a Delaware corporation and subsidiary of Heat Biologics Inc., having business offices at 627 Davis Drive, Suite 400, Morrisville, North Carolina 27560 (“LICENSEE”). For purposes of this Agreement, each of UNIVERSITY and LICENSEE may be individually referred to as a “Party” and collectively referred to as the “Parties.”
Re: Separation AgreementSeparation Agreement • January 6th, 2021 • Heat Biologics, Inc. • Pharmaceutical preparations • North Carolina
This letter sets forth the substance of the Separation Agreement (the “Agreement”) which the Company is offering to you. The Separation Agreement contains a general release that, among other statutes and claims, applies to rights and claims arising under the Age Discrimination in Employment Act of 1967 (29 U.S.C. §621 et seq.), as well as the Older Workers’ Benefit Protection Act of 1990. Before executing this Agreement, you are advised to consult an attorney to review its contents. You may consider this Agreement for 21 calendar days from the date you receive this Agreement and General Release before executing it. Discussions or negotiations about this Agreement and General Release do not extend this 21day period beyond the next business day (at which time this offer is revoked) unless agreed to by the Company in writing. In addition, if you execute the agreement, you may revoke the Separation Agreement and General Release for up to seven calendar days. Details are provided below.
January 4, 2021 William Ostrander c/o Heat Biologics, Inc.Offer Letter • January 6th, 2021 • Heat Biologics, Inc. • Pharmaceutical preparations
